Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

JOHNSON & JOHNSON : Credit Suisse reiterates its Buy rating

06/01/2021 | 06:26am EDT

Analyst Matt Miksic from Credit Suisse research considers the stock attractive and recommends it with a Buy rating. The target price is still set at USD 193.


© MarketScreener with dpa-AFX Analyser 2021
All news about JOHNSON & JOHNSON
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
AQ
07/23GLOBAL MARKETS LIVE : Intel, HoneyWell, American Express, Visa, Twitter...
07/23JOHNSON & JOHNSON : UBS Adjusts Johnson & Johnson's Price Target to $183 From $1..
MT
07/23ASTRAZENECA : EU On Track To Donate 200 Million COVID-19 Vaccine Doses In 2021
MT
07/22JOHNSON & JOHNSON : Opioid-ravaged West Virginia looks to $26B deal for help
AQ
07/22JOHNSON & JOHNSON : In opioid-ravaged WVa, potential deal raises hopes for help
AQ
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
AQ
07/22JOHNSON & JOHNSON : Covid-19 Vaccines - Current Challenge Is Not Supply but Usin..
AQ
07/21CARDINAL HEALTH : States reach $26B opioid settlement with Johnson & Johnson, 'b..
AQ
07/21JOHNSON & JOHNSON : Strong Q2 from J&J as pandemic-hit sales, profit recover
AQ
More news
Financials (USD)
Sales 2021 94 447 M - -
Net income 2021 22 808 M - -
Net Debt 2021 871 M - -
P/E ratio 2021 20,2x
Yield 2021 2,40%
Capitalization 452 B 452 B -
EV / Sales 2021 4,80x
EV / Sales 2022 4,58x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 171,79 $
Average target price 184,35 $
Spread / Average Target 7,31%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246
ABBVIE INC.10.30%199 548